842,669 Shares in Lantern Pharma Inc. $LTRN Purchased by Empery Asset Management LP

Empery Asset Management LP purchased a new position in shares of Lantern Pharma Inc. (NASDAQ:LTRN) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 842,669 shares of the company’s stock, valued at approximately $3,513,930. Lantern Pharma accounts for 0.0% of Empery Asset Management LP’s investment portfolio, making the stock its 7th largest holding. Empery Asset Management LP owned 6.60% of Lantern Pharma as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in LTRN. XTX Topco Ltd bought a new position in shares of Lantern Pharma during the second quarter worth about $40,000. Vanguard Group Inc. lifted its holdings in Lantern Pharma by 5.6% during the third quarter. Vanguard Group Inc. now owns 384,041 shares of the company’s stock worth $1,671,000 after acquiring an additional 20,321 shares in the last quarter. Two Sigma Investments LP bought a new stake in Lantern Pharma during the third quarter worth $70,000. Susquehanna International Group LLP acquired a new position in shares of Lantern Pharma in the 3rd quarter valued at approximately $170,000. Finally, Geode Capital Management LLC lifted its stake in shares of Lantern Pharma by 5.1% in the 4th quarter. Geode Capital Management LLC now owns 96,742 shares of the company’s stock valued at $293,000 after purchasing an additional 4,661 shares during the period. Institutional investors and hedge funds own 28.62% of the company’s stock.

Lantern Pharma Stock Down 2.8%

Shares of NASDAQ:LTRN traded down $0.06 during trading on Friday, reaching $2.10. The stock had a trading volume of 58,935 shares, compared to its average volume of 321,103. The stock has a fifty day simple moving average of $3.04 and a two-hundred day simple moving average of $2.81. The firm has a market capitalization of $26.84 million, a price-to-earnings ratio of -1.30 and a beta of 2.34. Lantern Pharma Inc. has a 52 week low of $1.11 and a 52 week high of $4.70.

Lantern Pharma (NASDAQ:LTRN) last posted its quarterly earnings data on Friday, August 14th. The company reported ($0.57) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.19).

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on LTRN shares. Weiss Ratings raised shares of Lantern Pharma from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, July 29th. Wall Street Zen cut Lantern Pharma from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company has an average rating of “Sell”.

Lantern Pharma Profile

Lantern Pharma, Inc is a clinical-stage oncology company leveraging artificial intelligence (AI) and machine learning to accelerate the discovery and development of targeted cancer therapies. Headquartered in Dallas, Texas, Lantern Pharma’s proprietary RADR® platform integrates large-scale genomic, transcriptomic and chemical data to identify novel drug candidates and predict patient populations most likely to benefit from treatment.

The company’s pipeline focuses on molecules designed to address cancers with high unmet medical need.